ARCHIVES

Brigham & Women’s Suspends Controversial Morcellation Study As Apparent “Difference of Opinion” with FDA Comes to Light

This article is from The Cancer Letter archive.

Vol. 40 No. Nov 26 special report | November 26, 2014

Download PDF Visit The Full Archive

Related Articles

Afinitor Increases Overall Survival To 3.5 Years in Phase III Trial

September 26, 2014

Proceedings Initiated Against Two Physicians At Dana-Farber

April 7, 1995

DCPC advisors OK New Grant Programs In Tobacco, Rural Area

November 12, 1993

NIH To Sponsor Animal Care, Human Protection Workshop

February 21, 1986

Price Increase

July 22, 1983

Nexavar Approved For Patients With Inoperable Liver Cancer

November 30, 2007